Literature DB >> 24557046

Targeting the inflammatory pathway as a therapeutic tool for major depression.

Cristiano Noto1, Lucas B Rizzo, Rodrigo B Mansur, Roger S McIntyre, Michael Maes, Elisa Brietzke.   

Abstract

In the last decades convergent findings from several lines of evidence has revealed a robust association between major depressive disorder (MDD) and inflammatory pathways. Despite this, the translation of these findings into new and better treatments for MDD has not occurred. The objective of this study is to comprehensively review what is already known with reasonable certainty on inflammatory pathways in MDD, to clarify some points that have been insufficiently studied and to discuss the implications of these findings for future studies targeting inflammatory pathways as a therapeutic tool for individuals with MDD.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24557046     DOI: 10.1159/000356549

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  13 in total

1.  Altered neuro-inflammatory gene expression in hippocampus in major depressive disorder.

Authors:  Gouri J Mahajan; Eric J Vallender; Michael R Garrett; Lavanya Challagundla; James C Overholser; George Jurjus; Lesa Dieter; Maryam Syed; Damian G Romero; Hamed Benghuzzi; Craig A Stockmeier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-11-22       Impact factor: 5.067

Review 2.  Immune-based strategies for mood disorders: facts and challenges.

Authors:  Gabriela D Colpo; Marion Leboyer; Robert Dantzer; Mahdukar H Trivedi; Antonio L Teixeira
Journal:  Expert Rev Neurother       Date:  2017-11-27       Impact factor: 4.618

Review 3.  Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.

Authors:  Amir Abdoli; Hoda Mirzaian Ardakani
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

Review 4.  Human dermal fibroblasts in psychiatry research.

Authors:  S Kálmán; K A Garbett; Z Janka; K Mirnics
Journal:  Neuroscience       Date:  2016-02-09       Impact factor: 3.590

5.  An altered peripheral IL6 response in major depressive disorder.

Authors:  Kelli M Money; Zita Olah; Zeljka Korade; Krassimira A Garbett; Richard C Shelton; Karoly Mirnics
Journal:  Neurobiol Dis       Date:  2016-01-22       Impact factor: 5.996

Review 6.  Role of neuro-immunological factors in the pathophysiology of mood disorders.

Authors:  Anindya Bhattacharya; Noel C Derecki; Timothy W Lovenberg; Wayne C Drevets
Journal:  Psychopharmacology (Berl)       Date:  2016-01-23       Impact factor: 4.530

7.  IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome.

Authors:  Chutima Roomruangwong; Buranee Kanchanatawan; Sunee Sirivichayakul; George Anderson; André F Carvalho; Sebastien Duleu; Michel Geffard; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-04-01       Impact factor: 5.590

8.  Catalpol ameliorates depressive-like behaviors in CUMS mice via oxidative stress-mediated NLRP3 inflammasome and neuroinflammation.

Authors:  Ya-Lin Wang; Hao-Ran Wu; Shan-Shan Zhang; Hong-Lei Xiao; Jin Yu; Yuan-Yuan Ma; Yao-Dong Zhang; Qiong Liu
Journal:  Transl Psychiatry       Date:  2021-06-08       Impact factor: 6.222

9.  Proinflammatory cytokines correlate with early exercise attenuating anxiety-like behavior after cerebral ischemia.

Authors:  Qi Zhang; Jingjun Zhang; Yuzhong Yan; Pengyue Zhang; Wei Zhang; Rong Xia
Journal:  Brain Behav       Date:  2017-10-18       Impact factor: 2.708

10.  Cyclophosphamide-induced cystitis results in NLRP3-mediated inflammation in the hippocampus and symptoms of depression in rats.

Authors:  Nathan A Hirshman; Francis M Hughes; Huixia Jin; William T Harrison; Simon W White; Isabelle Doan; Shelby N Harper; Patrick D Leidig; J Todd Purves
Journal:  Am J Physiol Renal Physiol       Date:  2019-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.